# ISM4808

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/ism4808
Canonical HTML page: https://getbiobrief.com/entity/ism4808

## Timeline

- **2026-03-06**: Phase I Initiation — First human subject enrolled and dosed in the Phase I clinical trial.
- **2025-Q1**: Out-Licensing Deal — TaiGen Biopharmaceuticals acquires rights for clinical development and commercialization.
- **2024-Q2**: Candidate Discovery — Insilico Medicine identifies ISM4808 using generative AI models.

## Recent coverage (1 stories)

### Insilico and TaiGen Advance AI-Derived CKD Anemia Candidate to Phase I
2026-03-06 12:39:49 · Sentiment: Positive · Impact: 6/10 · Sources: 3

Insilico Medicine and TaiGen Biopharmaceuticals have achieved a major clinical milestone with the first human dosing of ISM4808, an AI-discovered small molecule for Chronic Kidney Disease (CKD) anemia. This Phase I trial marks a critical validation point for Insilico’s Pharma.AI platform and triggers a milestone payment from TaiGen.
Full story: https://getbiobrief.com/story/insilico-taigen-ism4808-phase-1-clinical-trial

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.